The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD

Inhaled corticosteroid/long-acting β(2)-agonist combination therapy is recommended in chronic obstructive pulmonary disease (COPD) patients at high risk of exacerbations. The EFFECT (Efficacy of Fluticasone propionate/FormotErol in COPD Treatment) trial is a Phase III, 52-week, randomized, double-bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Papi, Alberto, Jones, Paul W, Dalvi, Prashant S, McAulay, Kirsten, McIver, Tammy, Dissanayake, Sanjeeva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648608/
https://www.ncbi.nlm.nih.gov/pubmed/26648706
http://dx.doi.org/10.2147/COPD.S93375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648608/
https://www.ncbi.nlm.nih.gov/pubmed/26648706
http://dx.doi.org/10.2147/COPD.S93375

Ejemplares similares